|
1
|
Tan XL, Moyer AM, Fridley BL, Schaid DJ,
Niu N, Batzler AJ, Jenkins GD, Abo RP, Li L, Cunningham JM, et al:
Genetic variation predicting cisplatin cytotoxicity associated with
overall survival in lung cancer patients receiving platinum-based
chemotherapy. Clin Cancer Res. 17:5801–5811. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rodriguez E and Lilenbaum RC: Small cell
lung cancer: Past, present, and future. Curr Oncol Rep. 12:327–334.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jackman DM and Johnson BE: Small-cell lung
cancer. Lancet. 366:1385–1396. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lowe JM, Menendez D, Bushel PR, Shatz M,
Kirk EL, Troester MA, Garantziotis S, Fessler MB and Resnick MA:
p53 and NF-κB coregulate proinflammatory gene responses in human
macrophages. Cancer Res. 74:2182–2192. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
O'Reilly S, Ciechomska M, Cant R and van
Laar JM: Interleukin-6 (IL-6) trans signaling drives a
STAT3-dependent pathway that leads to hyperactive transforming
growth factor-β (TGF-β) signaling promoting SMAD3 activation and
fibrosis via Gremlin protein. J Biol Chem. 289:9952–9960. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Greijer AE, de Jong MC, Scheffer GL,
Shvarts A, van Diest PJ and van der Wall E: Hypoxia-induced
acidification causes mitoxantrone resistance not mediated by drug
transporters in human breast cancer cells. Cell Oncol. 27:43–49.
2005.PubMed/NCBI
|
|
8
|
Daniel C, Bell C, Burton C, Harguindey S,
Reshkin SJ and Rauch C: The role of proton dynamics in the
development and maintenance of multidrug resistance in cancer.
Biochim Biophys Acta. 1832:606–617. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tavares-Valente D, Baltazar F, Moreira R
and Queirós O: Cancer cell bioenergetics and pH regulation
influence breast cancer cell resistance to paclitaxel and
doxorubicin. J Bioenerg Biomembr. 45:467–475. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yamazaki R, Nishiyama Y, Furuta T, Hatano
H, Igarashi Y, Asakawa N, Kodaira H, Takahashi H, Aiyama R,
Matsuzaki T, et al: Novel acrylonitrile derivatives, YHO-13177 and
YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and
in vivo. Mol Cancer Ther. 10:1252–1263. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim DH, Sriharsha L, Xu W, Kamel-Reid S,
Liu X, Siminovitch K, Messner HA and Lipton JH: Clinical relevance
of a pharmacogenetic approach using multiple candidate genes to
predict response and resistance to imatinib therapy in chronic
myeloid leukemia. Clin Cancer Res. 15:4750–4758. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Doyle L and Ross DD: Multidrug resistance
mediated by the breast cancer resistance protein BCRP (ABCG2).
Oncogene. 22:7340–7358. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Robey RW, Medina-Pérez WY, Nishiyama K,
Lahusen T, Miyake K, Litman T, Senderowicz AM, Ross DD and Bates
SE: Overexpression of the ATP-binding cassette half-transporter,
ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast
cancer cells. Clin Cancer Res. 7:145–152. 2001.PubMed/NCBI
|
|
14
|
Ke SZ, Ni XY, Zhang YH, Wang YN, Wu B and
Gao FG: Camptothecin and cisplatin upregulate ABCG2 and MRP2
expression by activating the ATM/NF-κB pathway in lung cancer
cells. Int J Oncol. 42:1289–1296. 2013.PubMed/NCBI
|
|
15
|
King D, Yeomanson D and Bryant HE: PI3King
the lock: Targeting the PI3K/Akt/mTOR pathway as a novel
therapeutic strategy in neuroblastoma. J Pediatr Hematol Oncol.
37:245–251. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jin HJ, Li HT, Sui HX, Xue MQ, Wang YN,
Wang JX and Gao FG: Nicotine stimulated bone marrow-derived
dendritic cells could augment HBV specific CTL priming by
activating PI3K-Akt pathway. Immunol Lett. 146:40–49. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jin HJ, Sui HX, Wang YN and Gao FG:
Nicotine up-regulated 4-1BBL expression by activating Mek-PI3K
pathway augments the efficacy of bone marrow-derived dendritic cell
vaccination. J Clin Immunol. 33:246–254. 2013. View Article : Google Scholar
|
|
18
|
Wang YY, Yang YW, You X, Deng XQ, Hu CF,
Zhu C, Wang JY, Gu JJ, Wang YN, Li Q, et al: Ex vivo nicotine
stimulation augments the efficacy of human peripheral blood
mononuclear cell-derived dendritic cell vaccination via activating
Akt-S6 pathway. Anal Cell Pathol. 2015:7414872015. View Article : Google Scholar
|
|
19
|
Wang SQ, Liu ST, Zhao BX, Yang FH, Wang
YT, Liang QY, Sun YB, Liu Y, Song ZH, Cai Y, et al: Afatinib
reverses multidrug resistance in ovarian cancer via dually
inhibiting ATP binding cassette subfamily B member 1. Oncotarget.
6:26142–26160. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xi G, Hayes E, Lewis R, Ichi S,
Mania-Farnell B, Shim K, Takao T, Allender E, Mayanil CS and Tomita
T: CD133 and DNA-PK regulate MDR1 via the PI3K- or Akt-NF-κB
pathway in multidrug-resistant glioblastoma cells in vitro.
Oncogene. 35:241–250. 2016. View Article : Google Scholar
|
|
21
|
de Souza PS, Cruz AL, Viola JP and Maia
RC: Microparticles induce multifactorial resistance through
oncogenic pathways independently of cancer cell type. Cancer Sci.
106:60–68. 2015. View Article : Google Scholar :
|
|
22
|
Wang R, Zhang J, Chen S, Lu M, Luo X, Yao
S, Liu S, Qin Y and Chen H: Tumor-associated macrophages provide a
suitable microenvironment for non-small lung cancer invasion and
progression. Lung Cancer. 74:188–196. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bhowmick NA, Neilson EG and Moses HL:
Stromal fibroblasts in cancer initiation and progression. Nature.
432:332–337. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang TH, Chan YH, Chen CW, Kung WH, Lee
YS, Wang ST, Chang TC and Wang HS: Paclitaxel (Taxol) upregulates
expression of functional interleukin-6 in human ovarian cancer
cells through multiple signaling pathways. Oncogene. 25:4857–4866.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Poth KJ, Guminski AD, Thomas GP, Leo PJ,
Jabbar IA and Saunders NA: Cisplatin treatment induces a transient
increase in tumorigenic potential associated with high
interleukin-6 expression in head and neck squamous cell carcinoma.
Mol Cancer Ther. 9:2430–2439. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Duan Z, Lamendola DE, Penson RT, Kronish
KM and Seiden MV: Overexpression of IL-6 but not IL-8 increases
paclitaxel resistance of U-2OS human osteosarcoma cells. Cytokine.
17:234–242. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chang CH, Hsiao CF, Yeh YM, Chang GC, Tsai
YH, Chen YM, Huang MS, Chen HL, Li YJ, Yang PC, et al: Circulating
interleukin-6 level is a prognostic marker for survival in advanced
nonsmall cell lung cancer patients treated with chemotherapy. Int J
Cancer. 132:1977–1985. 2013. View Article : Google Scholar
|
|
28
|
Wójcik E, Jakubowicz J, Skotnicki P,
Sas-Korczyńska B and Kulpa JK: IL-6 and VEGF in small cell lung
cancer patients. Anticancer Res. 30:1773–1778. 2010.PubMed/NCBI
|
|
29
|
Nikiteas NI, Tzanakis N, Gazouli M, Rallis
G, Daniilidis K, Theodoropoulos G, Kostakis A and Peros G: Serum
IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients:
Prognostic implications. World J Gastroenterol. 11:1639–1643. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lee SO, Lou W, Johnson CS, Trump DL and
Gao AC: Interleukin-6 protects LNCaP cells from apoptosis induced
by androgen deprivation through the Stat3 pathway. Prostate.
60:178–186. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Domingo-Domenech J, Oliva C, Rovira A,
Codony-Servat J, Bosch M, Filella X, Montagut C, Tapia M, Campás C,
Dang L, et al: Interleukin 6, a nuclear factor-κB target, predicts
resistance to docetaxel inhormone-independent prostate cancer and
nuclear docetaxel antitumor activity. Clin Cancer Res.
12:5578–5586. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yan HQ, Huang XB, Ke SZ, Jiang YN, Zhang
YH, Wang YN, Li J and Gao FG: IL-6 augments lung cancer
chemotherapeutics resistance via ATM/NF-kappaB pathway activation.
Cancer Sci. 105:1220–1227. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jiang YN, Yan HQ, Huang XB, Wang YN, Li Q
and Gao FG: Interleukin 6 trigged ataxia-telangiectasia mutated
activation facilitates lung cancer metastasis via MMP-3/MMP-13
up-regulation. Oncotarget. 6:40719–40733. 2015.PubMed/NCBI
|
|
34
|
Shiloh Y and Ziv Y: The ATM protein
kinase: Regulating the cellular response to genotoxic stress, and
more. Nat Rev Mol Cell Biol. 14:197–210. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Svirnovski AI, Serhiyenka TF, Kustanovich
AM, Khlebko PV, Fedosenko VV, Taras IB and Bakun AV: DNA-PK, ATM
and MDR proteins inhibitors in overcoming fludarabine resistance in
CLL cells. Exp Oncol. 32:258–262. 2010.
|
|
36
|
Wu ZH, Wong ET, Shi Y, Niu J, Chen Z,
Miyamoto S and Tergaonkar V: ATM- and NEMO-dependent ELKS
ubiquitination coordinates TAK1-mediated IKK activation in response
to genotoxic stress. Mol Cell. 40:75–86. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen J, Wang J, Chen D, Yang J, Yang C,
Zhang Y, Zhang H and Dou J: Evaluation of characteristics of
CD44+CD117+ ovarian cancer stem cells in
three dimensional basement membrane extract scaffold versus two
dimensional monocultures. BMC Cell Biol. 14:72013. View Article : Google Scholar
|
|
38
|
Grimm M, Krimmel M, Polligkeit J,
Alexander D, Munz A, Kluba S, Keutel C, Hoffmann J, Reinert S and
Hoefert S: ABCB5 expression and cancer stem cell hypothesis in oral
squamous cell carcinoma. Eur J Cancer. 48:3186–3197. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shi Y, Liu C, Liu X, Tang DG and Wang J:
The microRNA miR-34a inhibits non-small cell lung cancer (NSCLC)
growth and the CD44hi stem-like NSCLC cells. PLoS One.
9:e900222014. View Article : Google Scholar
|
|
40
|
Sarvi S, Mackinnon AC, Avlonitis N,
Bradley M, Rintoul RC, Rassl DM, Wang W, Forbes SJ, Gregory CD and
Sethi T: CD133+ cancer stem-like cells in small cell
lung cancer are highly tumorigenic and chemoresistant but sensitive
to a novel neuropeptide antagonist. Cancer Res. 74:1554–1565. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang Y, Wang SX, Ma JW, Li HY, Ye JC, Xie
SM, Du B and Zhong XY: EGCG inhibits properties of glioma stem-like
cells and synergizes with temozolomide through downregulation of
P-glycoprotein inhibition. J Neurooncol. 121:41–52. 2015.
View Article : Google Scholar
|
